Transforming patient management with smart technology Smart Patient Management Azure™ Pacemaker with BlueSync™ Technology

Improved Longevity1

AF Detection and Reduction2 Introducing Azure with BlueSync™ Technology, the first pacemaker that connects with a IMPROVED smartphone or tablet without compromising longevity and building on best in class AF detection and reduction. LONGEVITY New hardware architecture optimises circuitry to reduce current drain and improve longevity. NEW PLATFORM DR +27% 13.7 WITH BLUESYNC TECHNOLOGY YEARS 5,6* BlueSync™ Technology enables secure wireless communication via Bluetooth® Low Energy without compromising longevity. 13.7 years* Key Design Changes 10.8 SR years* 15.8 Bluetooth® YEARS 7,8* Low Energy (BLE) High Density Encryption Module Integrated Circuit reduces current drain for Data are encrypted in the pacemaker improved longevity using NIST* standard encryption

Advisa DR MRITM Azure DR *NIST: National Institute of Standards and technology (US Department of Commerce). * Bluetooth® Low Energy: ON; 500 ohm; 2.5 V; pre-storage EGM: OFF; DR: MVP™; SR: VVI 50%.

SMART AF DETECTION PATIENT MANAGEMENT AND REDUCTION MyCareLink Heart™ mobile App has been designed Azure offers AF detection and reduction algorithms with clinically proven efficiency. to enhance: Detect AF Reduce AF Reduce AT/AF false positives with PR Logic™9 Reactive ATP™ Patient compliance, leading to increased clinic efficiency3 algorithms Reactive ATP is associated with a 10 Patient engagement, promoting patient satisfaction4 AF Episode Detection Accuracy (PPV) * 40% 40% reduced risk of persistent AF2** MyCareLink Heart mobile App 100% 9, 11, 12 Patient access to newest technology due to ease of app upgrades on patient's smartphone 90% 95-96% MVP 80% 83%13 Now updated with the option to 70% control maximum AV interval 60% 62%14 50% MVP algorithm reduces unnecessary 13 15 40% 48% RV pacing by 99%.

30% AV conduction RV pacing is associated with a 1% Azure with BlueSync MyCareLink Heart mobile App Cellular CareLink™ 20% 2:1 or greater for a minimum of Episodes Episodes increase in risk of AF for each 1% Technology on patient’s smartphone* or Wi-Fi network > 6 Minutes ≤6 minutes 10% 24 V cycles A Rate > 170 bpm increase in cumulative RV apical (acts as a pass-through only) (~20sec) A Rate > 190 bpm 4 A cycles 0% pacing.16 Select data Medtronic St. Jude Medical Boston Scientific (content of transmissions and alerts are not visible to the patient)

*Please visit www.MCLHeart.com for a list of compatible smartphones and tablets. * AF detection accuracy rates determined from independant clinical ** MVP is only available in DR models. Reactive ATP trials are presented for reference is only available in Azure XT DR. UNMATCHED mRI Access

With Azure™ Pacemaker, patients have access to 1.5T and 3T full body scanning16

Built to be scanned § Our SureScan™ devices and leads work in any combination. § Scanning conditions are simple: no MRI exclusion zone, no patient height restriction, no MRI duration restriction.16

References 14 nowak B, McMeekin J, Knops M, et al., and on behalf of the Stored EGM 1 orenga M. Azure longevity Increase Compared to Advisa. September in PulsarMax II and Discovery II Study Group. Validation of dual-chamber 2017. Medtronic data on file. pacemaker diagnostic data using dual-channel stored electrograms. Pacing Clin Electrophysiol. July 2005;28(7):620-629. 2 Hudnall H. Reactive Atrial-based Antitachycardia Pacing Therapy to Slow 15 Progression of Atrial Fibrillation. August 2017, Medtronic data on file. gillis AM, et al. Reducing unnecessary right ventricular pacing with the 3 managed ventricular pacing mode in patients with sinus node disease and Cronin EM, Ching EA, Varma N, Martin DO, Wilkoff BL, Lindsay BD. AV block.PACE 2006; 29:697–705. Remote monitoring of cardiovascular devices: a time and activity analysis. 16 Heart Rhythm. December 2012;9(12):1947-1951. sweeney MO, Hellkamp AS, Ellenbogen KA, et al. Adverse effect of 4 ventricular pacing on heart failure and atrial fibrillation among patients Varma N. Remote monitoring of patients with CIEDs following the with normal baseline QRS duration in a clinical trial of pacemaker therapy updated recommendations — Easing or adding to postimplant for sinus node dysfunction. Circulation. June 17, 2003;107(23):2932- responsibilities? Cont. Cardiol Educ. December 2016;2(4):198-204. 2937. 5 m964362A001 C Azure™ XT DR MRI SureScan™ W2DR01. Device 17 m964378001B Azure™ MRI SureScan™/Astra™ MRI SureScan™ pacing manual. systems MRI Technical Manual. 6 m964363A001 B Azure™ S DR MRI SureScan™ W3DR01. Device manual. 7 m964364A001 B Azure™ XT SR MRI SureScan™ W2SR01. Device manual. 8 m964365A001 B Azure™ S SR MRI SureScan™ W3SR01. Device manual. Brief Statement 9 purerfellner H, et al. Accuracy of Atrial Tachyarrhythmia Detection See the MRI SureScan® manual before performing an MRI Scan and the in Implantable Devices with Arrhythmia Therapies. Pacing Clin device manual for detailed information regarding the instructions for use, Electrophysiol. July 2004;27:983-992. the implant procedure, indications, contraindications, warnings, precautions, 10 sprenger M. Comparison of Manufacturer’s AT/AF Detection Accuracy and potential adverse events. For further information, contact your local across Clinical Studies. January 2015. Medtronic data on file. Medtronic representative and/or consult the Medtronic website at www. medtronic.com. 11 Ziegler PD. Accuracy of Atrial Fibrillation Detection in Implantable Pacemakers. Heart Rhythm. 2013;10:S147 [PO02-08] 12 medtronic Data on File. QADoc DSN026170, Version 2.0, “AT/AF Duration Performance Comparison.” 13 Kauffman ES, Israel CW, Nair GM, et al. Positive predictive value of device- detected atrial high-rate episodes at different rates and durations: a n Consult instructions for use at this website. Manuals can be viewed using a analysis from ASSERT. Heart Rhythm. August 2012;9(8):1241-1246. current version of any major Internet browser. For best results, use Adobe Acrobat Reader® with the browser.

All rights reserved. Medtronic, Medtronic logo, and Further, Together are trademarks of Medtronic. The Bluetooth® word mark and logos are registered trademarks owned by Bluetooth SIG, Inc. and any use of such marks by Medtronic is under license.™ Other third party brands are trademarks of their respective owners. All other brands are trademarks of a Medtronic company.

Europe United Kingdom/Ireland Medtronic International Medtronic Limited Trading Sàrl. Building 9 Route du Molliau 31 Croxley Park Case postale Hatters Lane CH-1131 Tolochenaz Watford Tel. +41 (0)21 802 70 00 Herts WD18 8WW Fax +41 (0)21 802 79 00 www.medtronic.co.uk Tel: +44 (0)1923 212213 UC201811761EE - © Medtronic 2018. medtronic.eu Fax: +44 (0)1923 241004 All rights reserved. Printed in Europe.